Namyang Dairy saw a surge in its shares after claiming its Bulgaris yogurt variants can help lower the risk of COVID-19 infection. The company's day trading on Wednesday, April 14, reportedly increased.
As per The Korea Herald, Namyang Dairy’s shares once shot up by 28.68% to KRW489,000 or around $437.39 in the early morning trading. It was added that within 20 minutes after the opening bell, the company’s preferred stocks also surge by the daily allowable limit of 29.78% to reach KRW231,000.
Prior to Wednesday’s results, it was reported that the firm’s shares went up 7.19% and 6.71% on Friday and Monday, respectively. It then increased again by 8.57% on Tuesday, and this shows that Namyang Dairy’s shares have been on the rise since last weekend and continued this week.
Namyang’s COVID-19 claim
Observers are saying that the company’s surge in shares may be due to its claims that its Bulgaris yogurt lineup can help reduce the risk of getting COVID-19. Some market insiders also think that some investors may have also used information that caused the hike in the recent stock tradings.
At any rate, what triggered the sudden increase in shares of Namyang Dairy was the statement given by the company during a news conference in Seoul.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Namyang’s chief of antiviral immune research center, Park Jong Su, said at that time. “Our experiments showed that Bulgaris helped remove the Influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
He added that the test of the yogurt’s effectiveness in fighting coronavirus was done using the lung cells of a monkey. As a result of this claim, people reportedly rushed out to purchase Namyang Dairy’s Bulgaris yogurts in stores.
Statement from S. Korea’s health officials
After the announcement from Namyang, the public health authorities released a statement. The agency expressed its concern over the claims.
“The latest research result has not proved to be effective in eliminating those viruses in the human body,” the Korea Disease Control and Prevention Agency stated. “Therefore, it is hard to say whether it can serve as an actual prevention or treatment measure for (the viruses).”


Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Oil Prices Rise on Venezuela Sanctions and Nigeria Airstrikes Despite Annual Losses
Oil Prices Edge Higher as Strong U.S. Growth and Supply Risks Support Market
Global Markets Rise as Tech Stocks Lead, Yen Strengthens, and Commodities Hit Record Highs
IMF Reaches Staff-Level Agreement With Egypt, Opening Path to $3.8 Billion in Funding
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
U.S. Stock Futures Edge Higher as Holiday-Thinned Trading Persists
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
U.S. Dollar Slips as Yen Finds Support on Intervention Signals and Geopolitical Risks Rise
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Wall Street Ends Higher as S&P 500, Nasdaq Extend Gains Ahead of Holiday Week 



